GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Arterra Bioscience SpA ARBS.MI · EUR

N/A · Borsa Italiana · 🇮🇹 Italy

Compare

3.00

-0.66%

Close of 9 Nov 2026, in EUR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in EUR, from our data supplier.

FY2025

Revenue

€4.6m

FY2017FY2025

Net income

€2.0m

FY2017FY2025

Free cash flow

€1.5m

FY2017FY2025

Shareholders' equity

€12.6m

FY2017FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue€4.6m€4.2m€3.3m€3.6m€4.7m€2.8m€2.7m€2.4m€2.1m
Research and development—€2.0m—€1.6m—————
Operating income€591,761€1.5m−€356,488€365,020€1.9m−€149,950€141,080€510,159€388,080
Net income€2.0m€1.3m€1.1m€1.4m€1.1m€1.1m€857,240€1.0m€745,258
Diluted earnings per share0.300.200.160.210.170.170.110.160.11

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets€14.6m€13.4m€12.6m€12.6m€11.6m€10.3m€9.6m€4.8m€3.5m
Cash and short-term investments€1.3m€3.3m€3.7m€6.0m€4.8m€4.5m€4.7m€737,481€248,536
Total liabilities€2.0m€2.0m€1.8m€2.1m€2.1m€2.1m€2.4m€2.2m€1.8m
Debt€260,351€356,429€386,084€489,312€614,499€809,292€1.0m€892,571€630,174
Shareholders' equity€12.6m€11.4m€10.8m€10.5m€9.5m€8.2m€7.1m€2.6m€1.7m
Shares outstanding7m7m7m7m7m7m8m7m7m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations€2.0m€1.1m€1.0m€1.4m€1.4m€479,886€1.7m€952,163€484,836
Capital spending−€453,293−€664,694−€82,705−€98,950−€609,120−€382,589−€1.6m−€535,615−€76,658
Free cash flow€1.5m€399,414€943,171€1.3m€787,838€97,297€128,677€416,548€408,178
Dividends paid−€846,700−€665,849−€665,849——−€113,239−€300,000−€200,000−€50,000

Latest quarters

By quarter end

Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022Jun 2022
Revenue€2.1m€2.6m€1.9m€2.6m€1.1m€1.6m€1.4m€2.1m
Operating income€184,948€406,813€297,007€511,197−€101,962−€555,060−€193,820€552,940
Net income€921,057€1.1m€819,445€517,260€827,541€248,610€735,365€678,659
Diluted earnings per share0.140.160.120.080.120.040.110.10
Cash from operations—€1.0m——————
Total assets€14.6m€14.0m€13.4m€12.5m€12.6m€12.4m€12.6m€11.9m
Cash and short-term investments€1.3m€3.4m€3.3m€3.4m€3.7m€6.0m€6.0m€5.5m
Debt€260,351€48,084€356,429€342,970€86,317€136,236€36,581€159,773
Shareholders' equity€12.6m€11.7m€11.4m€10.6m€10.8m€10.0m€10.5m€9.7m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue9.0%10.5%—
Operating income17.5%——
Net income12.4%12.6%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Price to earnings10.09.810.310.217.416.835.7
Price to sales4.33.13.34.04.16.611.3

Dividends and splits

Per share, in the currency the company pays

Paid for 4 years. Last went ex-dividend on 5 May 2025.

FY2025FY2024FY2023FY2022
Paid in the year0.130.2020.100.05

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.